Mitochondriotropic Nanoemulsified Genistein-Loaded Vehicles for Cancer Therapy
Genistein (Gen), a major soy isoflavone, produces extensive pro-apoptotic anticancer effects, mediated predominantly via induction of mitochondrial damage. Based on several biophysical model criteria, our rational assumptions for the native mitochondrial selectivity of Gen allowed its design as a cationic lipid-based nanocarrier (NC) system. Proof-of-concept nano-formulations, lipidic micelles (Mic), and nanoemulsions (NEs) incorporated Gen, which serves as therapeutic and targeting moieties, specific for mitochondria. Our in vitro experimental data demonstrated superior physicochemical properties and significant cytotoxicity of Gen-NCs (five- to tenfolds lower EC50) compared to all drug controls, in hepatic and colon carcinomas. The established mitochondria-specific accumulation of the various Gen-NCs positively correlated with marked mitochondrial depolarization effects. Within first 24 h, Gen-NC treatments ultimately lead to distinct activation of intrinsic apoptotic pathway markers, such as cytosolic cytochrome c and specific caspase-9 vs. nonspecific caspases-3, 7, and 8. Such mechanistic evidence of the mitochondriotropic activity of our Gen-NC platforms favors their prospective as intracellularly targeted delivery nano-vehicles, to enhance anticancer efficacy of different co-formulated chemotherapeutic agents.
Key wordsIsoflavone Mitochondrial damage Mitochondriotropic Genistein Caspase enzymes Cytochrome c Apoptosis
- 6.Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Tasken KA, Karlsen SJ (2011) Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer 63:889–898CrossRefPubMedGoogle Scholar
- 8.Yoshimura FK (2004) Genistein induces apoptosis via mitochondrial damage in acute lymphoblastic leukemia T-cell lines. Cancer Therapy 2:429–440Google Scholar
- 13.Merchant K, Kumi-Diaka J, Rathinavelu A, Esiobu N, Zoeller R, Hartmann J, Johnson M (2011) Molecular basis of the anti-cancer effects of genistein isoflavone in LNCaP prostate cancer cells. Funct Food Health Dis 1:91–105Google Scholar
- 14.Stancanelli R, Guardo M, Cannava C, Guglielmo G, Ficarra P, Villari V, Micali N, Mazzaglia A (2010) Amphiphilic cyclodextrins as nanocarriers of genistein: a spectroscopic investigation pointing out the structural properties of the host/drug complex system. J Pharm Sci 99:3141–3149PubMedGoogle Scholar